Skip to main content
EMA Logo
  • Medicines
    Medicines

    • Search
    • Download
    • What we publish and when
    • Medicines under evaluation
    • National registers
    • Medicines for use outside the EU
  • Human regulatory
    Human regulatory

    • Overview
    • Research and development
    • Marketing authorisation
    • Post-authorisation
    • Herbal products
  • Veterinary regulatory
  • Committees
    Committees

    • How the committees work
    • CHMP
    • CVMP
    • PRAC
    • COMP
    • HMPC
    • CAT
    • PDCO
    • Working parties and other groups
  • News & events
    News & events

    • News and press releases
    • Events
    • What's new
    • Committee highlights
    • Therapeutic areas: latest updates
    • Publications
    • Press and social media
    • Open consultations
    • RSS feeds
  • Partners & networks
    Partners & networks

    • EU partners
    • International activities
    • Patients and consumers
    • Healthcare professionals
    • Academia
    • Pharmaceutical industry
    • Networks
    • Health technology assessment bodies
  • About us
    About us

    • What we do
    • Who we are
    • How we work
    • Annual reports and work programmes
    • History of EMA
    • Careers
    • Procurement
    • Support to research
    • Contact
    • Legal
    • Glossary
    • Search tips
    • FAQs
    • Brexit: UK withdrawal from EU
Veterinary regulatory

  • Overview
  • Research and development
  • Marketing authorisation
  • Post-authorisation
  • Availability of veterinary vaccines
  • Compliance
  • Ethical use of animals
  • Innovation in medicines
  • Maximum residue limits
  • Minor uses / minor species and limited markets
  • Quality by design
  • Scientific advice
  • Scientific guidelines
    • Search guidelines
    • Quality
      • Non-immunologicals
      • Availability
      • Post approval change management protocols
    • Q&A on quality
    • Safety and residues
    • Efficacy
    • Immunologicals
    • Novel therapies

Quality: availability (minor uses / minor species)

The European Medicines Agency's scientific guidelines on the availability of veterinary medicinal products for minor use/minor species help medicine developers prepare marketing authorisation applications.

For a complete list of scientific guidelines currently open for consultation, see Public consultations.

Guidelines

  • CVMP guidelines on data requirements for veterinary medicinal products intended for minor uses or minor species
  • Quality data requirements for veterinary medicinal products intended for minor use or minor species (MUMS)/limited market

Related content

  • Scientific guidelines on quality
  • Scientific guidelines

Topics

  • Guidance
  • Quality of medicines
  • Research and development
  • Scientific guidelines

How useful was this page?

Add your rating
Product emergency hotline
outside working hours
About
  • Who we are
  • Human regulatory
  • Veterinary regulatory
  • Committees
Ask EMA
  • Send a question
  • FAQs
  • Access to documents
Links
  • Legal
  • Privacy
  • Complaints
  • Contacts
  • Glossary
  • Search tips
  • Business hours and holidays
Contact

European Medicines Agency
Domenico Scarlattilaan 6
1083 HS Amsterdam
The Netherlands

Tel: +31 (0)88 781 6000

For delivery address, see:
How to find us

For the United Kingdom, as of 1 January 2021, European Union law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland / NI.
RSS feed Twitter YouTube LinkedIn
© 1995-2021 European Medicines Agency
European Union agencies network
European Union agencies network
An agency of the European Union
European Union flag